110448-33-4 Usage
Description
ML-7 inhibits smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 μM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. It exhibits a 10-fold more potent inhibition of MLCK than its parent compound ML-9 .
Chemical Properties
Off-White to Yellow Fine Crystalline Solid
Uses
ML-7 has been used as a myosin light chain kinase (MLCK) inhibitor in various experiments.
Biochem/physiol Actions
Selective myosin light chain kinase inhibitor.
in vitro
rats with myocardial infarction were intravenously infused with rhnrg-1. the cmlck expression and phosphorylated mlc-2v were up-regulated in rat treated with rhnrg-1 significantly. moreover, the restoration of rhnrg-1-induced sarcomeric organization in serum-free cultured neonatal rat cardiomyocytes with rhnrg-1 was inhibited by ml-7 [1].
in vivo
administration of ml-7 from 10 min before ischemia to the first 10 min of reperfusion led to a significant recovery of heart contractility. gel analyses of two-dimensional electrophoresis revealed eight proteins with decreased levels in i/r hearts. six proteins involved in energy metabolism, which were cytochrome b-c1 complex subunit 1, atp synthase beta subunit, cytochrome c oxidase subunit, mitochondrial nadhdehydrogenase, nadhdehydrogenase iron-sulfur protein 8, and succinyl-coa ligase subunit. the other two protein levels decreased in i/r hearts, which were peroxiredoxin-2 and tubulin. in addition, ml-7 treatment increased the level of succinyl-coa ligase, which was a key enzyme involved in the citric acid cycle [2].
references
[1] gu x,liu x,xu d,li x,yan m,qi y,yan w,wang w,pan j,xu y,xi b,cheng l,jia j,wang k,ge j,zhou m. cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. cardiovasc res.2010 nov 1;88(2):334-43. [2] lin hb,cadete vj,sawicka j,wozniak m,sawicki g. effect of the myosin light chain kinase inhibitor ml-7 on the proteome of hearts subjected to ischemia-reperfusion injury. j proteomics.2012 sep 18;75(17):5386-95.
Check Digit Verification of cas no
The CAS Registry Mumber 110448-33-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,4,4 and 8 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 110448-33:
(8*1)+(7*1)+(6*0)+(5*4)+(4*4)+(3*8)+(2*3)+(1*3)=84
84 % 10 = 4
So 110448-33-4 is a valid CAS Registry Number.
